Am J Psychiatry 158:2071-2074, December 2001
© 2001 American Psychiatric Association
A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia
Wayne S. Fenton, M.D.,
Faith Dickerson, Ph.D.,
John Boronow, M.D.,
Joseph R. Hibbeln, M.D., and
Michael Knable, D.O.
OBJECTIVE: This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder. METHOD: Eighty-seven patients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despite neuroleptic treatment were randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or placebo (N=44) in a 16-week, double-blind supplementation trial. Assessments were performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive battery was administered at baseline and at week 16. RESULTS: No differences were found between groups in positive or negative symptoms, mood, cognition, or global impression ratings. Results were similar for the intention-to-treat (N=87) and completer (N=75) groups. CONCLUSIONS: For schizophrenia patients treated with 3 g/day of ethyl EPA, improvement in residual symptoms and cognitive impairment was no greater than for schizophrenia patients treated with placebo.
This article has been cited by other articles:
|
|
|
|
 
G. P. Amminger, M. R. Schafer, K. Papageorgiou, C. M. Klier, S. M. Cotton, S. M. Harrigan, A. Mackinnon, P. D. McGorry, and G. E. Berger
Long-Chain {omega}-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Arch Gen Psychiatry,
February 1, 2010;
67(2):
146 - 154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Lewis, R. Y. Cho, C. S. Carter, K. Eklund, S. Forster, M. A. Kelly, and D. Montrose
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
Am J Psychiatry,
December 1, 2008;
165(12):
1585 - 1593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M Appleton, R. C Hayward, D. Gunnell, T. J Peters, P. J Rogers, D. Kessler, and A. R Ness
Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials
Am. J. Clinical Nutrition,
December 1, 2006;
84(6):
1308 - 1316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder
Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids
Nutr Clin Pract,
August 1, 2006;
21(4):
323 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Noaghiul and J. R. Hibbeln
Cross-National Comparisons of Seafood Consumption and Rates of Bipolar Disorders
Am J Psychiatry,
December 1, 2003;
160(12):
2222 - 2227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. B. Dickerson, J. J. Boronow, C. Stallings, A. E. Origoni, I. Ruslanova, and R. H. Yolken
Association of Serum Antibodies to Herpes Simplex Virus 1 With Cognitive Deficits in Individuals With Schizophrenia
Arch Gen Psychiatry,
May 1, 2003;
60(5):
466 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. HORROBIN
Omega-3 Fatty Acid for Schizophrenia
Am J Psychiatry,
January 1, 2003;
160(1):
188 - 189.
[Full Text]
|
|
|
|
|
|
|
C. M. Wilk, J. M. Gold, J. J. Bartko, F. Dickerson, W. S. Fenton, M. Knable, C. Randolph, and R. W. Buchanan
Test-Retest Stability of the Repeatable Battery for the Assessment of Neuropsychological Status in Schizophrenia
Am J Psychiatry,
May 1, 2002;
159(5):
838 - 844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peet
Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression
Adv. Psychiatr. Treat.,
May 1, 2002;
8(3):
223 - 229.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
